Chlorprothixene

As a typical thioxanthene antipsychotic drug, chlorprothixene exerts its effect by blocking dopamine D2 receptors in the mesolimbic and mesocortical pathways, while also having a certain antagonistic effect on 5-hydroxytryptamine 2A receptors. It can effectively control the positive symptoms of schizophrenia such as hallucinations, delusions and thought disorder, and also has certain sedative and anxiolytic effects. It is especially suitable for schizophrenia patients accompanied by emotional depression or anxiety, and can also be used for the symptomatic treatment of manic episodes and reactive psychosis. It is a cost-effective treatment option in the primary mental health service system.

In the current global antipsychotic generic drug market, first-generation antipsychotic drugs still account for about 23% of the primary market share due to their accessibility advantage. As a commonly used variety among them, chlorprothixene has maintained a compound annual growth rate of approximately 4.1% in global API demand in the past three years. The market supply is dominated by generic pharmaceutical enterprises in China and India, and the market share of the original research product has been less than 5%. In terms of the domestic market, this variety has not been included in the national centralized volume-based procurement, the procurement demand of medical institutions is stable, the competition pattern of the API supply side is relatively scattered, and no leading enterprise has formed a monopoly advantage for the time being.

The original research enterprise of chlorprothixene is Lundbeck Pharma in Denmark, with the original brand name Tardan, and the core compound patent expired worldwide in 1987. The main dosage form approved for the original research product is tablet, with specifications including 12.5mg, 25mg and 50mg. Its tablets have been included in the FDA Reference Listed Drug Catalog, and are also included in the second volume of the Chinese Pharmacopoeia 2025 Edition. As of the search time point, there are 3 registration entries of chlorprothixene API on the domestic CDE API Registration Platform, among which 2 are in status A, which can be used for associated preparation declaration. A number of domestic pharmaceutical enterprises have been approved to produce chlorprothixene tablets, with sufficient market supply. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of impurity reference standards for chlorprothixene, most of which are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All products meet the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can fully meet the needs of API manufacturers and preparation R&D institutions for quality research, stability study and registration declaration.